Abstracts Archive - Page 1107 of 2607 - ACR Meeting Abstracts

Abstract Number: 2504 • 2019 ACR/ARP Annual Meeting
Differential Expression of Human Endogenous Retroviruses in Psoriatic Disease
Remy Pollock¹, Rohan Machhar ¹, Laila Zaman ¹, Dafna Gladman ² and Vinod Chandran ³, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, Canada
Background/Purpose: Human endogenous retroviruses (HERV) are the stably inherited remnants of ancient retroviruses that infected the ancestral germline. A growing body of research has associated…
Abstract Number: 2505 • 2019 ACR/ARP Annual Meeting
Can Biologics “Prevent” the Development of Psoriatic Arthritis in Psoriasis Patients? Data from a Large University Hospital Cohort in Argentina
Luciano Fernando Lo Giudice¹, Maria Laura Acosta Felquer ¹, Luis Daniel Mazzuoccolo ², Maria Laura Galimberti ² and Enrique Soriano ³, ¹Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, ²Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina
Background/Purpose: As psoriasis (Pso) commonly precedes psoriatic arthritis (PsA), an important unanswered question is whether treatment of Pso might influence the development of PsA in…
Abstract Number: 2506 • 2019 ACR/ARP Annual Meeting
The ‘Severity of Nail Psoriasis Score’ (SNAPS) Is Feasible, Reliable and Demonstrates Construct Validity Against the mNAPSI in an Observational Cohort of Patients with Psoriatic Arthritis
Anna Antony¹, Darren Hart ², Charlotte Cavill ³, Eleanor Korendowych ⁴, Neil McHugh ⁵, Christopher Lovell ⁴ and William Tillett ⁴, ¹Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Melbourne, Victoria, Australia, ²Department of Clinical Measurement, Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, England, United Kingdom, ³Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, United Kingdom, ⁴Royal National Hospital for Rheumatic Diseases, Royal United Hospitals NHS Trust, Bath, England, United Kingdom, ⁵University of Bath, Bath, England, United Kingdom
Background/Purpose: Background: Longitudinal assessment of psoriatic nail dystrophy and its response to treatment is limited outside of research settings due to the complexity of existing…
Abstract Number: 2507 • 2019 ACR/ARP Annual Meeting
The Impact of Psoriasis Severity on Outcomes Among Psoriatic Arthritis Patients Receiving Adalimumab
Joseph Merola¹, Laura Coates ², Elizabeth M Lesser ³, Wendell C Valdecantos ³, Yanna Song ⁴ and Philip Mease ⁵, ¹Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, ²University of Oxford, Oxford, United Kingdom, ³AbbVie Inc., North Chicago, ⁴AbbVie Inc., North Chicago, IL, USA, North Chicago, ⁵Swedish Medical Center/Providence St Joseph Health, and University of Washington, Seattle, WA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous, chronic, immune mediated disease associated with psoriasis (PsO), with varying skin severity which can range from mild to…
Abstract Number: 2508 • 2019 ACR/ARP Annual Meeting
Large Joint and Lower Extremity Involvement Has Higher Impact on Disease Outcomes in Oligoarticular PsA
Gizem Ayan¹, Dilek Solmaz ², Sibel Bakirci ³, Ilaria Tinazzi ⁴, Ahmet Omma ⁵, Orhan Küçükşahin ⁶, Cem Ozisler ⁷, Sule Yavuz ⁸, Ozun Bayindir ⁹, Gezmiş Kimyon ¹⁰, Atalay Dogru ¹¹, Emine Figen Tarhan ¹², Meryem Can ¹³, Levent Kilic ¹⁴, Mehmet Tuncay Duruoz ¹⁵, Kenan Aksu ¹⁶, Umut Kalyoncu ¹⁷ and Sibel Zehra Aydin ¹⁸, ¹University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, Canada, ²Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ³Antalya Education and Research Hospital, Antalya, Turkey, ⁴Sacro Cuore Don Calabria Hospital, Unit of Rheumatology, Verona, Italy, ⁵Ankara Numune Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁶Liv Hospital, Ankara, Turkey, ⁷Diskapi Yildirim Beyazit Education and Research Hospital, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁸Uppsala University, Istanbul, Turkey, ⁹Ege University, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ¹⁰Mustafa Kemal University, Hatay, Turkey, ¹¹Suleyman Demirel University, Department of Internal Medicine, Division of Rheumatology, Isparta, Turkey, ¹²Mugla Sitki Kocman University, Department of Internal Medicine, Division of Rheumatology Mugla,, Mugla, Turkey, ¹³Marmara University, Division of Rheumatology, Istanbul, Turkey, Istanbul, Turkey, ¹⁴Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ¹⁵Marmara University School of Medicine, Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Istanbul, Turkey, ¹⁶Ege University, Department of Internal Medicine, Division of Rheumatology, Izmir, ¹⁷Hacettepe University Department of Rheumatology, Ankara, Turkey, ¹⁸University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada
Background/Purpose: Joints with different sizes (e.g. small and large joints) and anatomical locations (upper and lower extremities) can be affected in psoriatic arthritis (PsA). Our…
Abstract Number: 2509 • 2019 ACR/ARP Annual Meeting
Psoriasis Impact on Patient-Reported Outcomes in Psoriatic Arthritis in a Real-World Setting: Results from the APOPSIS Study
Panagiotis Athanassiou ¹, Athina Theodoridou ², Eftychia Maria Koukli ³, Athanasios Georgountzos ⁴, Panagiotis Vlachoyiannopoulos ⁵, Ioannis Kallitsakis ⁶, Lazaros Sakkas ⁷, Aikaterini Matsouka Dapola ⁸, Souzana Gazi ⁹, Panagiotis Georgiou ¹⁰, Patricia Gorecki ¹¹ and Christos Gkamaloutsos¹², ¹General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, ²Private Practice, Thessaloniki, Greece, ³Private Practice, Kifisia-Athens, Greece, ⁴General Hospital of Athens “G. Gennimatas”, Athens, Greece, ⁵University General Hospital of Athens “Laiko”, Athens, Greece, ⁶Private Practice, Chania, Greece, ⁷University General Hospital of Larissa, Larissa, Greece, ⁸Private Practice, Cholargos-Athens, Greece, ⁹General Hospital of Athens “KAT”, Athens, Greece, ¹⁰General Hospital of Patras “Agios Andreas”, Patras, Greece, ¹¹Janseen-Cilag UK, High Wycombe, United Kingdom, ¹²Janssen-Cilag Pharmaceutical SACI(Greece), Athens, Greece
Background/Purpose: Psoriatic arthritis (PsA) is a chronic progressive inflammatory arthropathy associated with psoriasis (PsO). PsA places a considerable burden, adversely affecting health-related quality of life…
Abstract Number: 2510 • 2019 ACR/ARP Annual Meeting
Validation of the Modified Stokes Ankylosing Spondylitis Spinal Score (mSASSS) as a Tool to Assess Axial PsA
Daniel Pau¹, Justine (Yang) Ye ², Sevket Tunc ³, Antonio Wong ³, Vinod Chandran ³, Richard Cook ⁴ and Dafna Gladman ⁵, ¹University of Toronto, Toronto, Canada, ²University Health Network, University of Toronto, Toronto, ON, Canada, ³University Health Network, University of Toronto, Toronto, Canada, ⁴University of Waterloo, Waterloo, Canada, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: Axial joint involvement commonly links psoriatic arthritis (PsA) to spondyloarthritis with widely variable prevalence (25-70%). Patients with axial PsA (AxPsA) are older than patients…
Abstract Number: 2511 • 2019 ACR/ARP Annual Meeting
What Influences Patients’ Opinion of Remission and Low Disease Activity in Psoriatic Arthritis? Principal Component Analysis of an International Study
Laura Coates¹, Danielle Robinson ², Ana-Maria Orbai ³, Uta Kiltz ⁴, Ying-Ying Leung ⁵, Penelope Palominos ⁶, Juan Cañete ⁷, Rossana Scrivo ⁸, Andra Balanescu ⁹, Emmanuelle Dernis ¹⁰, Sandra Talli ¹¹, Adeline Ruyssen-Witrand ¹², Lihi Eder ¹³, Maarten de Wit ¹⁴, Josef Smolen ¹⁵, Ennio Lubrano ¹⁶ and Laure Gossec ¹⁷, ¹University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital,, Singapore, Singapore, ⁶Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul,, Porto Alegra, Brazil, ⁷Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, ⁸Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza Università di Roma,, Rome, Italy, ⁹Sf Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, ¹⁰Rheumatology Department, Le Mans Central Hospital, Le Mans, France, ¹¹Rheumatology Department, East-Tallinn Central Hospital, Tallinn, Estonia, ¹²Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, ¹³Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ¹⁴Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ¹⁵Medical University of Vienna, Vienna, Austria, ¹⁶15. Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ’Vincenzo Tiberio’, University of Molise, Campobasso, Italy, ¹⁷Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: In psoriatic arthritis (PsA), the objective of treatment is remission or low disease activity (LDA), but there is little research into patients’ perception of…
Abstract Number: 2512 • 2019 ACR/ARP Annual Meeting
A Qualitative Study of Clinicians’ Perspectives on Barriers to Implementation of Treat to Target in Psoriatic Arthritis
Julie Taylor ¹, Laura Coates² and Emma Dures ¹, ¹Department of Nursing and Midwifery, University of the West of England, Bristol and Academic Rheumatology, University Hospitals NHS Trust, Bristol, England, United Kingdom, ²University of Oxford, Oxford, United Kingdom
Background/Purpose: European League Against Rheumatism Treatment recommendations support implementing a treat-to-target (T2T) approach in psoriatic arthritis (PsA) based on the findings of the TICOPA trial.…
Abstract Number: 2513 • 2019 ACR/ARP Annual Meeting
Relationships Between Psoriatic Arthritis Disease Activity Score and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Laura Coates¹, Andrew Bushmakin ², Oliver FitzGerald ³, Dafna Gladman ⁴, Lara Fallon ⁵, Joseph Cappelleri ², Ming-Ann Hsu ⁶ and Philip Helliwell ⁷, ¹University of Oxford, Oxford, United Kingdom, ²Pfizer Inc, Groton, CT, ³University College Dublin, Dublin, Ireland, ⁴University of Toronto, Toronto, ON, Canada, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷University of Leeds, Leeds, United Kingdom
Background/Purpose: Psoriatic arthritis (PsA) is a complex heterogeneous disease associated with multiple domains. Psoriatic Arthritis Disease Activity Score (PASDAS) is a composite disease activity measure…
Abstract Number: 2514 • 2019 ACR/ARP Annual Meeting
Relationships Between Minimal Disease Activity and Patient-Reported Outcomes in Patients with Psoriatic Arthritis: Post Hoc Analysis of Two Phase 3 Studies
Philip Helliwell¹, Andrew Bushmakin ², Dafna Gladman ³, Oliver FitzGerald ⁴, Lara Fallon ⁵, Joseph Cappelleri ², Ming-Ann Hsu ⁶ and Laura Coates ⁷, ¹University of Leeds, Leeds, United Kingdom, ²Pfizer Inc, Groton, CT, ³University of Toronto, Toronto, ON, Canada, ⁴University College Dublin, Dublin, Ireland, ⁵Pfizer Inc, Montreal, QC, Canada, ⁶Pfizer Inc, Collegeville, PA, ⁷University of Oxford, Oxford, United Kingdom
Background/Purpose: PsA is associated with multiple disease domains, requiring the use of different clinical measures and patient-reported outcomes (PROs) to assess improvements in disease activity…
Abstract Number: 2515 • 2019 ACR/ARP Annual Meeting
Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Artrhitis
Natalia Palmou-Fontana¹, DAVID MARTINEZ-LOPEZ ², ALFONSO CORRALES ³, Fernanda Genre ⁴, SUSANA ARMESTO ⁵, MARCOS GONZALEZ ⁶, PATRICIA VICENTE-GOMEZ ⁷, JAVIER GARCIA-FERNANDEZ ⁶, VIRGINIA PORTILLA- GONZALEZ ⁵, MONICA PEREZ-ANDRES ⁵, Mónica Calderón-Goercke ⁸, DIANA PRIETO- PENA ¹, Ricardo Blanco ⁹, JOSE LUIS HERNANDEZ ¹⁰, MIGUEL ANGEL GONZALEZ-GAY ¹¹ and Iván Ferraz-Amaro ¹², ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ³Universitary Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ⁵UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, Cantabria, Spain, ⁶UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, Cantabria, Spain, ⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁸Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ¹⁰UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, ¹¹UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, ¹²Rheumatology Division, Hospital Universitario de Canarias, Tenerife, Spain, Tenerife, Spain
Background/Purpose: Objectives. The addition of carotid ultrasound CU into composite cardiovascular risk (CVR) scores has been found useful in the identification of high CVR in…
Abstract Number: 2516 • 2019 ACR/ARP Annual Meeting
Development of a Biomarker Panel for Prediction of Disease Flares in Systemic Lupus Erythematosus
Serena Fasano¹, Luciana Pierro ¹, Alessia Borgia ¹, Melania Coscia ¹, Ranieri Formica ¹, antonella Riccardi ¹ and Francesco Ciccia ¹, ¹University of Campania L. Vanvitelli, Naples, Italy
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease with a relapsing-remitting course. Uncontrolled lupus flares might lead to organ damage. The routinely performed biomarkers…
Abstract Number: 2517 • 2019 ACR/ARP Annual Meeting
Hydroxychloroquine Is a Modifiable Predictor of Durable LLDAS
Hakan Babaoglu¹, Jessica Li ², Daniel Goldman ³, Laurence Magder ⁴ and Michelle Petri ², ¹Gazi University School of Medicine, Ankara, Turkey, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: The Lupus Low Disease Activity State (LLDAS), a potential treat to target goal in systemic lupus erythematosus (SLE), has been found to correlate with…
Abstract Number: 2518 • 2019 ACR/ARP Annual Meeting
Time to Lupus Low Disease Activity State: Role of African-American Ethnicity
Hakan Babaoglu¹, Jessica Li ², Daniel Goldman ³, Laurence Magder ⁴ and Michelle Petri ², ¹Gazi University School of Medicine, Ankara, Turkey, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Lupus Low Disease Activity State (LLDAS) is a potential treat to target goal in systemic lupus erythematosus (SLE). It is well established that SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].